Glooko Stock

glooko.comHealthcare / Other HealthcareFounded: 2010Funding to Date: $521.83MM

Glooko is a healthcare technology company which offers a diabetes management platform to healthcare providers, patients, and pharmaceutical companies. The platform is designed to integrate with hundreds of diabetes devices to gather and analyze patient data. Through comprehensive data centralization and analytical tools, Glooko aims to enhance diabetes management and facilitate clinical research in the field. This company was founded by Yogen Dalal, Sundeep Madra, and Chamath Palihapitiya in 2010 and is headquartered in Palo Alto, CA.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Glooko, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Glooko Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Glooko Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
10/10/2024 Series F $100MM $xx.xx $475.64MM Canaan, Georgian Partners, Health Catalyst Capital
Price per Share
$xx.xx
Shares Outstanding
41,407,867
Liquidation Pref Order
1
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan, Georgian Partners, Health Catalyst Capital
08/18/2023 Series E-Prime $30.56MM $xx.xx $318.34MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
12,652,982
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
08/18/2023 Series E $30.56MM $xx.xx $318.34MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
12,652,982
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
03/16/2021 Series D-Prime $10MM $xx.xx $150.67MM Canaan Partners, Georgian, Health Catalyst Capital, Insulet, Mayo Clinic, Novo Nordisk
Price per Share
$xx.xx
Shares Outstanding
7,510,886
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Georgian, Health Catalyst Capital, Insulet, Mayo Clinic, Novo Nordisk
03/16/2021 Series D $20MM $xx.xx $150.67MM Canaan Partners, Georgian, Health Catalyst Capital, Insulet, Mayo Clinic, Novo Nordisk
Price per Share
$xx.xx
Shares Outstanding
15,021,772
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Georgian, Health Catalyst Capital, Insulet, Mayo Clinic, Novo Nordisk
06/27/2017 Series C-1-Prime $13.01MM $xx.xx $116.76MM Canaan Partners, Georgian Partners, Insulet, Mayo Clinic, Medtronic, Samsung, Social Capital
Price per Share
$xx.xx
Shares Outstanding
10,335,930
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Georgian Partners, Insulet, Mayo Clinic, Medtronic, Samsung, Social Capital
06/27/2017 Series C-1 $13.29MM $xx.xx $116.76MM Canaan Partners, Georgian Partners, Insulet, Mayo Clinic, Medtronic, Samsung, Social Capital
Price per Share
$xx.xx
Shares Outstanding
10,562,032
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Georgian Partners, Insulet, Mayo Clinic, Medtronic, Samsung, Social Capital
09/17/2016 Series C-Prime $8.35MM $xx.xx $135.3MM Canaan Partners, Samsung, Social Capital, Yogen Dalal
Price per Share
$xx.xx
Shares Outstanding
4,130,876
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.1x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Samsung, Social Capital, Yogen Dalal
09/17/2016 Series C $8.35MM $xx.xx $135.3MM Canaan Partners, Samsung, Social Capital, Yogen Dalal
Price per Share
$xx.xx
Shares Outstanding
4,130,876
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Samsung, Social Capital, Yogen Dalal
03/17/2015 Series B-Prime $8.25MM $xx.xx $85.02MM Canaan Partners, Medtronic, Samsung, Social Capital
Price per Share
$xx.xx
Shares Outstanding
6,061,808
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Medtronic, Samsung, Social Capital
03/17/2015 Series B $8.25MM $xx.xx $85.02MM Canaan Partners, Medtronic, Samsung, Social Capital
Price per Share
$xx.xx
Shares Outstanding
6,061,808
Liquidation Pref Order
6
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Medtronic, Samsung, Social Capital
01/08/2014 Series A-1-Prime $3.5MM $xx.xx $25.22MM Lifeforce Ventures, Samsung, Social Capital, Sundeep Madra, Yogen Dalal
Price per Share
$xx.xx
Shares Outstanding
4,504,968
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Lifeforce Ventures, Samsung, Social Capital, Sundeep Madra, Yogen Dalal
01/08/2014 Series A-1 $3.5MM $xx.xx $25.22MM Lifeforce Ventures, Samsung, Social Capital, Sundeep Madra, Yogen Dalal
Price per Share
$xx.xx
Shares Outstanding
4,504,968
Liquidation Pref Order
7
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Lifeforce Ventures, Samsung, Social Capital, Sundeep Madra, Yogen Dalal
01/30/2012 Series A-Prime $1.15MM $xx.xx $29.2MM Andy Hertzfeld, Bill Campbell, Judy Estrin, Russell Hirsch, Social Capital, Venky Harinarayan, Vint Cerf, Xtreme Labs
Price per Share
$xx.xx
Shares Outstanding
115,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
5.6x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andy Hertzfeld, Bill Campbell, Judy Estrin, Russell Hirsch, Social Capital, Venky Harinarayan, Vint Cerf, Xtreme Labs
01/30/2012 Series A $1.15MM $xx.xx $29.2MM Andy Hertzfeld, Bill Campbell, Judy Estrin, Russell Hirsch, Social Capital, Venky Harinarayan, Vint Cerf, Xtreme Labs
Price per Share
$xx.xx
Shares Outstanding
115,000
Liquidation Pref Order
8
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
5.6x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andy Hertzfeld, Bill Campbell, Judy Estrin, Russell Hirsch, Social Capital, Venky Harinarayan, Vint Cerf, Xtreme Labs
11/09/2011 Series Seed-Prime $500,000.00 $xx.xx $5MM Anand Agarawala, Andy Hertzfeld, Bill Campbell, Judy Estrin, Russel Hirsch, Social Capital, Venky Harinarayan and Annad Rajaraman, Vint Cerf, Xtreme Labs
Price per Share
$xx.xx
Shares Outstanding
250,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
2.1x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Anand Agarawala, Andy Hertzfeld, Bill Campbell, Judy Estrin, Russel Hirsch, Social Capital, Venky Harinarayan and Annad Rajaraman, Vint Cerf, Xtreme Labs
11/09/2011 Series Seed $500,000.00 $xx.xx $5MM Anand Agarawala, Andy Hertzfeld, Bill Campbell, Judy Estrin, Russel Hirsch, Social Capital, Venky Harinarayan and Annad Rajaraman, Vint Cerf, Xtreme Labs
Price per Share
$xx.xx
Shares Outstanding
250,000
Liquidation Pref Order
8
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
2.1x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Anand Agarawala, Andy Hertzfeld, Bill Campbell, Judy Estrin, Russel Hirsch, Social Capital, Venky Harinarayan and Annad Rajaraman, Vint Cerf, Xtreme Labs

Glooko Investors Also Invested in These Private Companies

Health Catalyst Capital
Novo Nordisk
Insulet
Yogen Dalal
Venky Harinarayan
Xtreme Labs
Realization Capital Partners
Bill Campbell
Medtronic
Venky Harinarayan and Annad Rajaraman
Russell Hirsch
Health Catalyst Capital Management
Sundeep Madra
Andy Hertzfeld
Russel Hirsch
Lifeforce Ventures
Judy Estrin
Anand Agarawala
Vint Cerf

Leadership & Board

Leadership

Stephen Lien
Chief Financial Officer
Michael Greenfield MD
Chief Medical Officer
Annie Wayne
Chief Financial Officer
Russ Johannesson
Chief Executive Officer
David Conn
Chief Commercial Officer

Board

Chamath Palihapitiya
Social Capital
Vint Cerf Ph.D
Yogen Dalal Ph.D
Brendon Kim
Samsung NEXT Ventures
Theodore Maidenberg
Social Capital
William Campbell
Russell Hirsch Ph.D
Sundeep Madra
Xtreme Labs
Wende Hutton
Canaan Partners

Glooko stock FAQs

plusminus

Can you buy Glooko stock?

As Glooko is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Glooko, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Glooko stock?

To invest in a private company like Glooko through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Glooko stock?

Yes, you may sell the Glooko stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Glooko stock?

If you hold private company shares of Glooko – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Glooko on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Glooko a public company?

No, Glooko is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Glooko’s stock price?

Glooko is a privately held company and therefore does not have a public stock price. However, you may access Glooko private market stock price with Forge Data.
plusminus

What is Glooko’s stock ticker symbol?

Glooko does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Glooko News and Media Highlights

Glooko Secures $100 Million Series F Financing and Appoints Mike Alvarez as Chief Executive Officer

Glooko, Inc., a global integrated digital health company connecting patients, providers, biopharma and medical device partners, today announced that it has secured a $100 million Series F financing. The Company’s Board of Directors also announced the appointment of Mike Alvarez as Chief Executive Officer. The financing round, led by Georgian, with investments from Health Catalyst Capital, Canaan and other investors and business partners, will support Glooko’s continued growth and product expansion in expert data insights, device integrations, clinical research and chronic condition support for healthcare providers around the world.

Diabetes company Glooko partners with insulin dosing app Hedia

Diabetes management firm Glooko is partnering with Denmark-based Hedia to incorporate its app into Glooko's remote monitoring platform. The Hedia Diabetes Assistant app, which gives bolus insulin dosing advice, will sync with Glooko's platform, allowing patients to share their diabetes data with healthcare providers. The integration is expected to launch in Europe in Q4 2023 and Q1 2024.

Glooko, Sanofi partner on insulin pen connectivity

Glooko and Sanofi have partnered to incorporate a connected device for insulin pens into Glooko's digital platform. The SoloSmart device works with Sanofi’s insulin injection pens and records the insulin dose, date and time of injection. This data can then be visualised on the Glooko app and shared with healthcare professionals for improved diabetes management. Sanofi plans to utilise Glooko's global presence in over 8,000 clinics to increase digital solutions accessibility. SoloSmart is not yet approved for marketing in the U.S.
Browse Insights
Updated on: Dec 4, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.